| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5602162 (Pediatric) | ORGANON LLC | Imidazole, triazole and tetrazole derivatives |
Jul, 2012
(11 years ago) | |
|
US5298520 (Pediatric) | ORGANON LLC | Triazole containing indole derivatives |
Dec, 2012
(11 years ago) | |
Maxalt is owned by Organon Llc.
Maxalt contains Rizatriptan Benzoate.
Maxalt has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Maxalt are:
- US5602162*PED
- US5298520*PED
Maxalt was authorised for market use on 29 June, 1998.
Maxalt is available in tablet;oral dosage forms.
The generics of Maxalt are possible to be released after 16 June, 2015.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jun 16, 2015 |
| New Patient Population(NPP) | Dec 16, 2014 |
Drugs and Companies using RIZATRIPTAN BENZOATE ingredient
Market Authorisation Date: 29 June, 1998
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of MAXALT before it's drug patent expiration?
More Information on Dosage
MAXALT family patents
